Today's cancer immunotherapy has become an effective cancer treatment, with ICBs approved for the treatment of multiple different cancers, the more common being ICB against cytotoxic T-lymphocyte antigen 4 or PD-1-PD-L1 axis.145. This evidence concerns the gene CD274 and cancer.